


RN 519187-96-3 CAPLUS
 CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-,
 (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 519187-23-6
 CMF C16 H21 N O2 S



CM 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:1006755 CAPLUS
 DOCUMENT NUMBER: 140:53444
 TITLE: Medicinal compositions improving brain function and
 method for improving brain function
 INVENTOR(S): Nakada, Yasushi; Nakagawa, Masaya; Ono, Satoshi
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003105830	A1	20031224	WO 2003-JP4292	20030403 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2488120	A1	20031224	CA 2003-2488120	20030403 <--
AU 2003236364	A1	20031231	AU 2003-236364	20030403 <--
AU 2003236364	B2	20080821		
BR 2003011780	A	20050315	BR 2003-11780	20030403 <--
EP 1514542	A1	20050316	EP 2003-760132	20030403 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1662232	A	20050831	CN 2003-813857	20030403 <--
CN 100375619	C	20080319		
NZ 537090	A	20060224	NZ 2003-537090	20030403 <--
NO 2004005158	A	20050310	NO 2004-5158	20041125 <--
IN 2004KN01836	A	20060804	IN 2004-KN1836	20041202 <--
ZA 2004009901	A	20060726	ZA 2004-9901	20041207 <--
MX 2004PA12534	A	20050419	MX 2004-PA12534	20041213 <--
US 20050250843	A1	20051110	US 2004-516320	20041213 <--
US 7342043	B2	20080311		
US 20080103126	A1	20080501	US 2007-957832	20071217 <--

PRIORITY APPLN. INFO.: JP 2002-173483 A 20020614 <--
 WO 2003-JP4292 W 20030403 <--
 US 2004-516320 A3 20041213

OTHER SOURCE(S): MARPAT 140:53444

IT 519187-97-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (medicinal compns. containing alkylether derivs. for improving brain
 function and method for improving brain function)


RN 519187-97-4 CAPLUS

CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-,
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 519187-23-6

CMF C16 H21 N O2 S




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:335103 CAPLUS
 DOCUMENT NUMBER: 138:353837
 TITLE: Preparation of thiophenylalkyl, benzofuranylalkyl, or naphthylalkyl ether derivatives or salts thereof
 INVENTOR(S): Saitoh, Akihito; Iwakami, Noboru; Takamatsu, Tamotsu
 PATENT ASSIGNEE(S): Toyama Chemical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035647	A1	20030501	WO 2002-JP10827	20021018 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2464358	A1	20030501	CA 2002-2464358	20021018 <--
AU 2002344107	A1	20030506	AU 2002-344107	20021018 <--
AU 2002344107	B2	20071101		
EP 1437353	A1	20040714	EP 2002-777882	20021018 <--
EP 1437353	B1	20070613		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013393	A	20050111	BR 2002-13393	20021018 <--
CN 1571786	A	20050126	CN 2002-820645	20021018 <--
HU 2005000017	A2	20050428	HU 2005-17	20021018 <--
NZ 532328	A	20050729	NZ 2002-532328	20021018 <--
AT 364604	T	20070715	AT 2002-777882	20021018 <--
ES 2287324	T3	20071216	ES 2002-777882	20021018 <--
ZA 2004002806	A	20050413	ZA 2004-2806	20040413 <--
NO 2004001531	A	20040415	NO 2004-1531	20040415 <--
MX 2004PA03541	A	20040722	MX 2004-PA3541	20040415 <--
IN 2004KNC0509	A	20060414	IN 2004-KN509	20040419 <--
US 20050070521	A1	20050331	US 2004-492774	20041007 <--
US 7087594	B2	20060808		
US 20060194781	A1	20060831	US 2006-416321	20060503 <--
PRIORITY APPLN. INFO.:			JP 2001-321381	A 20011019 <--
			WO 2002-JP10827	W 20021018 <--
			US 2004-492774	A3 20041007

OTHER SOURCE(S): MARPAT 138:353837
 IT 519187-15-6P 519187-16-7P 519187-17-8P
 519187-18-9P 519187-21-4P 519187-22-5P
 519187-23-6P 519187-24-7P 519187-25-8P
 519187-30-5P 519187-96-3P 519187-97-4P
 519187-98-5P 519187-99-6P 519188-00-2P
 519188-01-3P 519188-02-4P 519188-03-5P
 519188-04-6P 519188-05-7P 519188-06-8P
 519188-07-9P 519188-08-0P 519188-09-1P
 519188-10-4P 519188-11-5P 519188-12-6P
 519188-13-7P 519188-14-8P 519188-15-9P
 519188-16-0P 519188-17-1P 519188-18-2P


519188-19-3P 519188-20-6P 519188-21-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiophenylalkyl, benzofuranylalkyl, or naphthylalkyl ether derivs. or salts thereof as nerve protectants, promoters of nerve regeneration, and potentiators of axon growth)


RN 519187-15-6 CAPLUS

CN 3-Azetidinol, 1-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]- (CA INDEX NAME)



RN 519187-16-7 CAPLUS


CN 3-Azetidinol, 1-[2-(2-benzo[b]thien-5-ylethoxy)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 519187-17-8 CAPLUS

CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-6-ylethoxy)propyl]- (CA INDEX NAME)



RN 519187-18-9 CAPLUS


CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-6-ylethoxy)propyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 519187-21-4 CAPLUS

CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-7-ylethoxy)propyl]- (CA INDEX NAME)



RN 519187-22-5 CAPLUS


CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-7-ylethoxy)propyl]-, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 519187-23-6 CAPLUS

CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]- (CA INDEX NAME)



RN 519187-24-7 CAPLUS

CN 3-Azetidinol, 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-,
(2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1